Pfizer (PFE) Tops Q4 EPS by 20c, Revenue Misses, Guidance Falls Short of Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Pfizer (PFE) Reiterated at Outperform by BMO Capital Following Earnings Report
February 8, 2022 7:47 AM ESTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $76.00 price target on Pfizer (NYSE: PFE), following the company's most recent earnings report.
The analyst quotes: "Good Enough 4Q21 results driven by an EPS beat; 2022 Guide light, but we see room... More
Pfizer (PFE) Reiterated at Overweight by Cantor Fitzgerald, "Confident PFE Can Meet its Guidance for a 5-year Revenue CAGR of at least 6%"
February 8, 2022 7:21 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $75.00 price target on Pfizer (NYSE: PFE), following the company's most recent earnings report.
The analyst quotes: "Post a mixed 4Q21 report (sales miss, fewer selling days and EPS beat), we are... More
